πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

6,867 results for β€œDe” Clear

  1. Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 3 small molecule completed

    5 trials

  2. Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Dependence

    phase 3 small molecule completed

    2 trials

  3. Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 3 small molecule active

    1 trial

  4. Buprenorphine + Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 3 small molecule completed

    1 trial

  5. Buprenorphine Injection

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 3 small molecule completed

    1 trial

  6. Buprenorphine Transdermal System

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Disease (or Disorder); Intervertebral Disc, With Myelopathy (Manifestation)

    phase 3 small molecule completed

    1 trial

  7. Buprenorphine/naloxone

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Dependence

    phase 3 small molecule completed

    2 trials

  8. Buprenorphine/naloxone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 3 small molecule terminated

    6 trials

  9. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 3 small molecule active

    3 trials

  10. Butylphthalide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Restenosis

    phase 3 small molecule completed

    1 trial

  11. Butylphthalide soft capsule

    NovaBridge Biosciences

    Vascular Dementia

    phase 3 small molecule active

    1 trial

  12. C1 esterase inhibitor [human] (C1INH-nf)

    Takeda

    Hereditary Angioedema

    phase 3 mab completed

    5 trials

  13. C1 esterase inhibitor [human] liquid

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  14. CALCIUM FOLINATE, IRINOTECAN HYDROCHLORIDE TRIHYDRATE, BEVACIZUMAB, BEVACIZUMAB, PANITUMUMAB, SOTORASIB, FLUOROURACIL

    Amgen

    Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  15. CALCIUM FOLINATE, OPDIVO 10 mg/mL concentrate for solution for infusion., BNT327 20 mg ml, OXALIPLATIN, FLUOROURACIL, BNT327 50 mg ml, CAPECITABINE, CAPECITABINE

    Bristol-Myers Squibb Australia Pty Ltd

    Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  16. CAM2029 (octreotide subcutaneous depot), CAM2029 (octreotide subcutaneous depot)

    Camurus Pty Ltd

    Acromegaly

    phase 3 small molecule active

    1 trial

  17. CAM2029 (octreotide subcutaneous depot), SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Somatuline Autogel 120 mg, solution for injection in a pre-filled syringe

    Camurus Pty Ltd

    gastroenteropancreatic neuroendocrine tumors

    phase 3 small molecule active

    1 trial

  18. CAPECITABINE, CAPECITABINE, CARBOPLATIN, Datopotamab deruxtecan, ERIBULIN MESYLATE, PACLITAXEL ALBUMIN-BOUND, PACLITAXEL

    AstraZeneca AB

    Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  19. CAPECITABINE, DS-8201a, INFLIXIMAB, CISPLATIN, MYCOPHENOLATE MOFETIL, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate for solution for infusion, FLUOROURACIL, Rilvegostomig, OXALIPLATIN, TRASTUZUMAB

    AstraZeneca AB

    HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

    phase 3 small molecule active

    1 trial

  20. CAPECITABINE, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Oxaliplatin 5mg/ml concentrate for solution for infusion, CETUXIMAB, ENCORAFENIB, Calcium Folinate 10 mg/ml Injection, CAMPTO 20 mg/mL concentrate for solution for infusion, Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion, CAMPTO 20 mg/mL concentrate for solution for infusion, FLUOROURACIL, IRINOTECAN, Bevacizumab, CALCIUM FOLINATE, Capecitabine, Cetuximab, OXALIPLATIN, Oxaliplatin 5mg/ml concentrate for Solution

    Pfizer Australia Pty Ltd

    Colorectal cancer (BRAF V600E-mutant mCRC)

    phase 3 small molecule active

    1 trial

  21. CAPECITABINE, PACLITAXEL, CAPECITABINE, DS-8201a, Abraxane 5 mg/ml powder for dispersion for infusion.

    AstraZeneca AB

    HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.

    phase 3 small molecule active

    1 trial

  22. CARBOPLATIN, CARBOPLATIN, IPILIMUMAB, PEMETREXED, CISPLATIN, INFLIXIMAB, PEMETREXED, Mycofit, 250 mg, kapsuΕ‚ki twarde, NIVOLUMAB, volrustomig

    AstraZeneca AB

    Unresectable Pleural Mesothelioma

    phase 3 small molecule active

    1 trial

  23. CARBOPLATIN, CARBOPLATIN, Patritumab deruxtecan, PEMETREXED, CISPLATIN

    Daiichi Sankyo

    Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  24. CARBOPLATIN, CISPLATIN, PEMETREXED, CARBOPLATIN, PEMETREXED, OSIMERTINIB, CISPLATIN, Telisotuzumab adizutecan, OSIMERTINIB, CARBOPLATIN, PEMETREXED

    AbbVie Deutschland GmbH & Co. KG

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources